Selecta Biosciences, Inc. (SELB) Upgraded at Zacks Investment Research
Selecta Biosciences, Inc. (NASDAQ:SELB) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a report released on Thursday.
According to Zacks, “Selecta Biosciences, Inc. is a biopharmaceutical company which develops targeted immunotherapies and vaccines. Its product pipelineincludes gene therapy, food allergy, malaria; SEL-212, which is a therapeutic enzyme indicated for refractory gout; SEL-070, which is indicated for smoking cessation and relapse prevention; SEL-701, which is indicated for the treatment of human papillomavirus associated cancer and SEL-212 consists of SVP-Rapamycin co-administered with pegsiticase, its pegylated uricase. Selecta Biosciences, Inc. is based in Watertown, United States. “
SELB has been the subject of a number of other research reports. ValuEngine downgraded shares of Selecta Biosciences from a “hold” rating to a “sell” rating in a research report on Tuesday, September 26th. Canaccord Genuity set a $25.00 target price on shares of Selecta Biosciences and gave the company a “buy” rating in a research report on Friday, August 11th. One investment analyst has rated the stock with a sell rating, one has given a hold rating and four have given a buy rating to the company. Selecta Biosciences has an average rating of “Buy” and an average price target of $27.75.
Selecta Biosciences (NASDAQ:SELB) opened at 22.28 on Thursday. Selecta Biosciences has a one year low of $10.27 and a one year high of $28.00. The company’s 50-day moving average is $19.13 and its 200-day moving average is $19.13. The firm’s market cap is $491.81 million.
Selecta Biosciences (NASDAQ:SELB) last released its earnings results on Friday, August 11th. The company reported ($0.85) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.86) by $0.01. The business had revenue of $0.03 million during the quarter. Selecta Biosciences had a negative net margin of 1,277.76% and a negative return on equity of 88.31%. On average, analysts forecast that Selecta Biosciences will post ($3.17) earnings per share for the current fiscal year.
COPYRIGHT VIOLATION WARNING: “Selecta Biosciences, Inc. (SELB) Upgraded at Zacks Investment Research” was originally reported by American Banking News and is the sole property of of American Banking News. If you are reading this piece on another website, it was stolen and republished in violation of US & international trademark & copyright laws. The correct version of this piece can be accessed at https://www.americanbankingnews.com/2017/10/12/selecta-biosciences-inc-selb-upgraded-at-zacks-investment-research.html.
In related news, Director Amir Nashat sold 147,187 shares of Selecta Biosciences stock in a transaction on Thursday, September 21st. The shares were sold at an average price of $19.91, for a total value of $2,930,493.17. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CFO David Siewers sold 16,424 shares of Selecta Biosciences stock in a transaction on Wednesday, September 20th. The shares were sold at an average price of $20.00, for a total transaction of $328,480.00. Following the completion of the sale, the chief financial officer now directly owns 2,194 shares of the company’s stock, valued at approximately $43,880. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 355,658 shares of company stock valued at $6,955,732. Insiders own 41.90% of the company’s stock.
Large investors have recently modified their holdings of the business. Nationwide Fund Advisors lifted its stake in Selecta Biosciences by 224.5% during the 2nd quarter. Nationwide Fund Advisors now owns 6,593 shares of the company’s stock valued at $131,000 after acquiring an additional 4,561 shares in the last quarter. Bank of New York Mellon Corp bought a new stake in shares of Selecta Biosciences during the 1st quarter worth $211,000. The Manufacturers Life Insurance Company raised its stake in shares of Selecta Biosciences by 827.0% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 11,254 shares of the company’s stock worth $224,000 after purchasing an additional 10,040 shares during the period. Rhumbline Advisers bought a new stake in shares of Selecta Biosciences during the 2nd quarter worth $239,000. Finally, New York State Common Retirement Fund raised its stake in shares of Selecta Biosciences by 184.0% during the 2nd quarter. New York State Common Retirement Fund now owns 12,500 shares of the company’s stock worth $248,000 after purchasing an additional 8,099 shares during the period. Institutional investors and hedge funds own 53.53% of the company’s stock.
Selecta Biosciences Company Profile
Selecta Biosciences, Inc is a clinical-stage biopharmaceutical company. The Company using its synthetic vaccine particle (SVP) technology to discover and develop targeted therapies that are designed to modulate the immune system to treat rare and serious diseases. The Company is engaged in the research and development of nanoparticle immunomodulatory drugs for the treatment and prevention of human diseases.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Selecta Biosciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Selecta Biosciences Inc. and related companies with MarketBeat.com's FREE daily email newsletter.